Pharmaceutical Fraud & Drug Diversion Schemes Investigation

Pharmaceutical fraud covers financial misconduct across the drug supply chain — from kickbacks and prescription manipulation to the diversion of controlled substances for illicit resale. It sits within the broader healthcare fraud practice but carries added regulatory weight because controlled substances involve both financial loss and patient-safety exposure. Forensic accountants investigate these schemes by reconciling drug inventory against dispensing and billing records to expose where product, money, or prescriptions have been manipulated. Federal agencies including the Drug Enforcement Administration, the Department of Justice, and the Department of Health and Human Services Office of Inspector General all have jurisdiction over different pieces of this problem, which is one reason pharmaceutical fraud cases tend to move slower and carry more regulatory weight than ordinary billing disputes.

What Pharmaceutical Fraud Covers and Why It Matters

Pharmaceutical fraud is an umbrella term for financial misconduct involving the manufacture, distribution, prescribing, dispensing, or billing of drugs, and it spans civil, criminal, and administrative exposure at the same time. A single scheme can trigger a False Claims Act action, a DEA registration revocation, and a state insurance fraud referral simultaneously, because the underlying conduct — diverting product, inflating reimbursement, or paying for prescriptions — violates several overlapping bodies of law at once.

What distinguishes pharmaceutical fraud from general healthcare billing fraud is the controlled-substance layer. The Controlled Substances Act (21 U.S.C. § 801 et seq.) imposes recordkeeping and reporting obligations on manufacturers, distributors, and pharmacies that do not exist for most other medical products, so an inventory shortfall in a Schedule II drug carries regulatory consequences beyond the dollar value of the product itself. Forensic accountants working these matters need to understand both the financial reconciliation side and the regulatory recordkeeping requirements that create the audit trail in the first place.

Red Flags That Point to Pharmaceutical Fraud

Pharmaceutical fraud rarely announces itself. It tends to surface first as a pattern anomaly — a number that does not reconcile, a prescriber whose volume looks statistically improbable, or a vendor relationship that cannot be explained on legitimate business terms. Recognizing these signals early is often what separates a routine audit finding from a case referred to counsel or regulators.

• Persistent inventory shrinkage in controlled substances that cannot be explained by waste, breakage, or documented returns.
• Prescribing spikes for a specific drug that correlate with payments, trips, or “speaker program” fees from the manufacturer.
• Unusual dispensing ratios — a pharmacy or clinic filling a disproportionate share of high-cost or high-diversion-risk drugs relative to its patient population.
• Billing for undispensed product, duplicate claims, or systematic upcoding to more expensive National Drug Code numbers.
• Round-number or patterned transactions in vendor or consulting payments that fail statistical distribution tests such as Benford’s Law, often used as a first-pass screening tool in larger data sets.
• Weak segregation of duties around ordering, receiving, and dispensing — the same conditions described in the ACFE’s occupational fraud research as enabling conditions for internal misappropriation generally.

None of these indicators proves fraud on its own. They function as triggers for deeper reconciliation work, the same way red flags function in any corporate fraud detection engagement — as a reason to look closer, not as a conclusion.

What Is Drug Diversion?

Drug diversion is the transfer of legitimately manufactured pharmaceuticals — especially controlled substances — out of the legal supply chain for illicit use or sale. It occurs at every level: manufacturers, distributors, pharmacies, hospitals, and individual providers. The financial signature is an inventory discrepancy: more product acquired than can be accounted for through legitimate dispensing, which forensic reconciliation is designed to detect.

Diversion investigations typically start with the DEA Form 222 and electronic Controlled Substance Ordering System records, since these documents establish exactly what quantity of a controlled substance entered a facility and when. From there, forensic accountants build a perpetual inventory model and compare it against dispensing logs, waste documentation, and return records. Any gap between what came in and what can be legitimately accounted for is the starting point for further inquiry, not the end of it — gaps can reflect genuine recordkeeping error as easily as theft, which is why reconciliation has to be exhaustive before conclusions are drawn.

Common Pharmaceutical Fraud Schemes

• Controlled substance diversion — theft or illicit resale of drugs, detected through inventory and dispensing analysis.
• Prescription fraud — forged, altered, or fabricated prescriptions, and “doctor shopping.”
• Kickback schemes — payments to prescribers to favor specific drugs, overlapping with corruption and procurement fraud.
• Billing fraud — upcoding, phantom prescriptions, and billing for undispensed drugs, connected to medical insurance fraud.
• Compounding and pricing fraud — manipulating formulations or prices to inflate reimbursement.

Several of these schemes rarely occur in isolation. A pharmacy engaged in billing fraud, for instance, often has weaker inventory controls generally, which makes it a more attractive target for diversion as well. Forensic engagements frequently uncover a layered pattern rather than a single discrete scheme, which is one reason document requests in these matters tend to be broad rather than narrowly scoped from the outset.

How Pharmaceutical Kickback Schemes Are Detected

Kickback schemes are financial arrangements disguised as legitimate payments — speaking fees, consulting arrangements, or research grants that are really inducements to prescribe. Forensic accountants detect them by correlating payment flows with prescribing behavior: a provider whose prescriptions for a particular drug spike in step with payments from its maker is a primary red flag. Establishing the link requires tracing the money and matching it against dispensing data over time.

This category of pharmaceutical fraud sits directly under the federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b) and often triggers parallel False Claims Act exposure, since claims submitted to Medicare or Medicaid that resulted from a kickback are treated as false claims regardless of whether the underlying prescription was medically appropriate. Publicly available data — including the Open Payments database maintained by the Centers for Medicare & Medicaid Services — gives investigators a starting point for correlating manufacturer payments against prescribing volume, but matching that public data against internal billing and payroll records is where the forensic work actually happens.

Prescribers are not the only actors in these arrangements. Pharmacy benefit managers, group purchasing organizations, and distributors can also receive disguised payments tied to formulary placement or purchasing volume, so a thorough kickback investigation traces money through the entire chain rather than stopping at the prescriber level.

How Forensic Accountants Investigate Pharmaceutical Fraud Cases

1. Inventory reconciliation — compare drugs purchased against drugs dispensed, billed, and returned to isolate discrepancies.
2. Dispensing pattern analysis — flag providers or facilities with anomalous volumes or drug mixes.
3. Financial flow tracing — follow payments between manufacturers, prescribers, and intermediaries.
4. Documentation review — authenticate prescriptions, contracts, and billing records.
5. Quantification and reporting — produce defensible loss figures and evidence for regulators and counsel.

Each step produces a work paper trail that has to withstand scrutiny in litigation or regulatory proceedings, which means methodology is documented as carefully as findings. A net-worth or bank-deposits analysis is sometimes layered onto this process when investigators need to establish that an individual’s lifestyle or asset accumulation is inconsistent with reported income — a method borrowed from tax fraud and embezzlement investigations that applies equally well to a prescriber or pharmacy owner suspected of profiting from a diversion scheme.

Documents and Evidence Reviewed in a Pharmaceutical Fraud Investigation

A pharmaceutical fraud investigation is only as strong as the records underlying it, and the document set is typically broader than a standard financial audit because it has to connect clinical, regulatory, and financial sources. Investigators generally request purchase and receiving records, DEA ordering forms, dispensing logs, electronic health records, point-of-sale and pharmacy management system exports, general ledger detail, vendor and consulting contracts, bank statements, and payroll records for anyone named in a suspected kickback arrangement.

Beyond the paper trail, interviews with pharmacy staff, billing personnel, and compliance officers help explain anomalies that documents alone cannot — a shift change that coincides with a shrinkage pattern, for example, or a verbal instruction to “round up” a dispensing count. Chain-of-custody documentation matters throughout, since any evidence intended for use in a regulatory referral, a False Claims Act qui tam action, or a civil suit needs to be defensible on authenticity grounds, not just accurate on the numbers. This is also where integrity monitoring arrangements become useful going forward, giving a facility an ongoing control rather than a one-time look-back.

Legal Context: Statutes and Agencies Involved in Pharmaceutical Fraud

Pharmaceutical fraud cases rarely involve a single statute or a single regulator, and understanding which agency has jurisdiction over which piece of the conduct shapes how an investigation is scoped. The Controlled Substances Act governs recordkeeping and diversion; the Anti-Kickback Statute and the Stark Law govern improper financial relationships between prescribers and industry; the federal False Claims Act (31 U.S.C. § 3729) governs fraudulent billing to government payers; and state insurance codes govern claims submitted to private payers.

On the enforcement side, the DEA investigates diversion, the FBI and DOJ pursue criminal kickback and fraud cases, HHS-OIG oversees Medicare and Medicaid program integrity and can exclude providers from federal health programs, and state attorneys general frequently bring parallel Medicaid fraud actions. Civil whistleblower suits under the False Claims Act’s qui tam provisions have historically been a major source of pharmaceutical fraud enforcement actions, since a person with inside knowledge of a kickback or billing scheme can file suit on the government’s behalf and share in any recovery. Counsel handling these matters often needs forensic support to translate the financial findings into the specific elements each statute requires — which is a natural overlap with white-collar defense work and with general fraud investigation and prevention engagements.

How Counsel and Clients Use Pharmaceutical Fraud Findings

Attorneys retain forensic accountants in pharmaceutical fraud matters for two related but distinct purposes: to determine what happened, and to present that determination in a form that survives cross-examination. A reconciliation that is accurate but undocumented is of limited use in litigation; the work has to show its method, cite its source documents, and be reproducible by an opposing expert working from the same records.

Findings from these engagements feed several different downstream processes. Compliance counsel may use them to support a voluntary self-disclosure to HHS-OIG, which can reduce penalty exposure compared to waiting for a government-initiated investigation. Litigation counsel may use them to support a civil suit against a manufacturer or distributor, often paired with asset tracing and recovery work if funds need to be located and recovered. Insurers rely on similar findings to support claim denials or subrogation actions. In nearly every scenario, the forensic accountant may be asked to testify as an expert witness, which means the underlying work paper file has to be built with that eventuality in mind from the first day of the engagement, not reconstructed afterward.

How MSN Forenzix Approaches Pharmaceutical Fraud Investigations

Our approach to a pharmaceutical fraud engagement begins with scoping: identifying which part of the supply chain is implicated, which records custodian holds the relevant data, and which statutes or claims counsel is evaluating, since that shapes what we collect and how we preserve it. From there we move into structured records collection — purchase and dispensing data, DEA ordering records, billing exports, and the financial records needed to trace payments between the parties involved.

Analysis follows a reconciliation-first discipline: inventory in versus inventory accounted for, payments made versus services or consulting work actually documented, and prescribing volume measured against statistically comparable peers. Where financial flows need to be traced between entities or into personal accounts, we apply the same tracing methodology used in our business asset tracing work. Every finding is documented in work papers that identify source, method, and assumptions, because that documentation is what allows the analysis to hold up under deposition or cross-examination. Final reporting is written for the audience that will use it — regulators, opposing counsel, or a trier of fact — and we support that reporting with expert witness testimony through our litigation support practice when the matter proceeds to court.

Scheme Type	Primary Evidence Reviewed	Typical Regulator/Statute Involved
Controlled substance diversion	DEA Form 222/CSOS records, dispensing logs, waste logs	DEA; Controlled Substances Act
Prescription fraud / doctor shopping	Prescription images, pharmacy dispensing history, state PDMP data	State medical/pharmacy boards; DEA
Kickback arrangements	Consulting contracts, Open Payments data, payroll and bank records	Anti-Kickback Statute; False Claims Act
Billing / upcoding fraud	Claims data, NDC codes, EHR records	HHS-OIG; False Claims Act; state insurance code
Compounding/pricing manipulation	Formulation records, cost build-ups, reimbursement claims	HHS-OIG; state pharmacy boards

This structure also shows why pharmaceutical fraud cases frequently require coordination across multiple professional disciplines — compliance counsel, litigation counsel, clinical reviewers, and forensic accountants each handle a piece that the others cannot. Our financial due diligence service is often the entry point when a buyer, insurer, or board first suspects a problem and needs a defensible preliminary assessment before deciding whether to escalate to a full investigation.

Frequently Asked Questions

What is drug diversion in healthcare?

Drug diversion is the movement of legitimately produced pharmaceuticals — especially controlled substances — out of the legal supply chain for illicit use or resale. It can occur at manufacturers, distributors, pharmacies, hospitals, or with individual providers, and its financial signature is an inventory discrepancy: more product acquired than legitimate dispensing records can explain.

How are pharmaceutical kickback schemes detected?

They are detected by correlating financial payments with prescribing behavior. Kickbacks are often disguised as consulting fees, speaking honoraria, or grants, so forensic accountants trace the money from manufacturer to prescriber and match it against dispensing data. Prescriptions that rise in step with payments are a primary indicator of an improper inducement.

What are common prescription fraud schemes?

Common schemes include forged or altered prescriptions, fabricated prescriptions, “doctor shopping” across multiple providers, billing for prescriptions never dispensed, and upcoding to more expensive drugs. Each leaves a trail in dispensing and billing records, which forensic reconciliation against inventory and payment data can expose.

Who investigates pharmaceutical fraud cases?

Pharmaceutical fraud is typically investigated by a combination of federal agencies, state regulators, and private forensic accountants working for counsel, insurers, or facility owners. The DEA handles diversion, HHS-OIG oversees Medicare and Medicaid program integrity, the FBI and DOJ pursue criminal referrals, and state attorneys general bring parallel Medicaid fraud actions. Forensic accountants are typically retained by counsel to perform the underlying financial reconciliation and tracing that supports any of these proceedings.

What penalties apply to pharmaceutical fraud under federal law?

Penalties vary by statute but can include criminal fines, imprisonment, civil monetary penalties, treble damages, and exclusion from federal health programs. False Claims Act violations, for example, carry civil penalties per false claim in addition to triple the government’s damages, while Anti-Kickback Statute violations carry both criminal and civil exposure. Because exposure differs by statute and by jurisdiction, anyone facing a potential pharmaceutical fraud allegation should consult qualified legal counsel rather than rely on general guidance.

Can forensic accountants help before an investigation becomes public?

Yes — forensic accountants are frequently engaged early, during an internal compliance review, before any regulator is involved. An early reconciliation can confirm whether an anomaly reflects genuine fraud or a recordkeeping error, which informs whether counsel recommends a voluntary self-disclosure or a more cautious wait-and-monitor approach. This kind of early-stage work overlaps closely with general financial fraud investigator engagements used across other industries.

Sources

Department of Justice

Drug Enforcement Administration